Olaparib in Treating Patients With Newly Diagnosed BRCA-Mutant Ovarian, Primary Peritoneal, or Fallopian Cancer Before Surgery
M.D. Anderson Cancer Center
M.D. Anderson Cancer Center
Zhejiang University
Ohio State University Comprehensive Cancer Center
Ohio State University Comprehensive Cancer Center
Cedars-Sinai Medical Center
H. Lee Moffitt Cancer Center and Research Institute
Memorial Sloan Kettering Cancer Center
Mayo Clinic
Jonsson Comprehensive Cancer Center
University of South Florida
Mayo Clinic
Peking University
Five Prime Therapeutics, Inc.
Haukeland University Hospital
Mayo Clinic
Beijing Kejing Biotechnology Co., Ltd.
OHSU Knight Cancer Institute
Mainline Biosciences, Inc.
Shanghai Yunying Medical Technology
OHSU Knight Cancer Institute
Shanghai Yunying Medical Technology
National Cancer Institute (NCI)
University of Oklahoma
The Christie NHS Foundation Trust
Shanghai Fengxian District Central Hospital
Roswell Park Cancer Institute
Shanghai 6th People's Hospital
Vastra Gotaland Region
Masonic Cancer Center, University of Minnesota
Mayo Clinic
Zhejiang University
H. Lee Moffitt Cancer Center and Research Institute
Mayo Clinic
Abramson Cancer Center at Penn Medicine
Vanderbilt-Ingram Cancer Center
Swedish Medical Center
Massachusetts General Hospital
National Institutes of Health Clinical Center (CC)
Case Comprehensive Cancer Center
Memorial Sloan Kettering Cancer Center